Alivus Life Sciences Limited (BOM:543322)

Market Cap	131.71B +7.0%
Revenue (ttm)	25.12B +10.5%
Net Income	5.44B +23.1%
EPS	44.23 +23.1%
Shares Out	n/a
PE Ratio	24.23
Forward PE	18.52
Dividend	5.00 (0.47%)
Ex-Dividend Date	Sep 1, 2025

Volume	6,739
Average Volume	5,439
Open	1,065.30
Previous Close	1,062.55
Day's Range	1,042.75 - 1,089.30
52-Week Range	830.00 - 1,224.00
Beta	n/a
RSI	72.29
Earnings Date	May 15, 2026

About Alivus Life Sciences

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health,...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2001
• Employees: 2,203
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543322

Financial Performance

In fiscal year 2025, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.